BioMed Realty, L.P. Prices Private Offering of $150.0 Million of 3.75% Exchangeable Senior Notes Due 2030
06 Janvier 2010 - 3:00AM
PR Newswire (US)
SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- BioMed Realty Trust,
Inc. (NYSE:BMR) today announced that its operating partnership
subsidiary, BioMed Realty, L.P., priced a private placement of
$150.0 million aggregate principal amount of 3.75% Exchangeable
Senior Notes due 2030 (the "Notes"). The operating partnership has
granted to the initial purchasers of the Notes a 30-day option to
purchase up to an additional $30.0 million aggregate principal
amount of Notes to cover over-allotments, if any. The Notes will be
senior unsecured obligations of the operating partnership, will be
fully and unconditionally guaranteed by BioMed Realty Trust and
will be exchangeable for shares of BioMed Realty Trust common
stock. The operating partnership intends to use the net proceeds
from the private offering to repay a portion of the outstanding
indebtedness under its unsecured line of credit and for other
general corporate and working capital purposes. The Notes will be
exchangeable at any time prior to the close of business on the
second scheduled trading day immediately preceding the maturity
date for shares of common stock of BioMed Realty Trust at an
initial exchange rate of 55.0782 shares per $1,000 principal amount
of Notes. The initial exchange price of approximately $18.16
represents a 20% premium over the last reported sale price per
share of BioMed Realty Trust's common stock on the New York Stock
Exchange on January 5, 2010, which was $15.13 per share. The
initial exchange rate is subject to adjustment in certain
circumstances. Prior to January 21, 2015, the Notes will not be
redeemable at the option of the operating partnership, except to
preserve BioMed Realty Trust's status as a real estate investment
trust. On or after January 21, 2015, the operating partnership may
redeem the Notes in whole or in part for cash at a redemption price
equal to the principal amount plus accrued and unpaid interest
(including additional interest), if any. The holders of the Notes
may require the operating partnership to repurchase all or a
portion of the Notes at a purchase price equal to the principal
amount plus accrued and unpaid interest (including additional
interest), if any, on the Notes on each of January 15, 2015, 2020
and 2025, and upon certain designated events. The Notes will be
sold to qualified institutional buyers in reliance on Rule 144A
under the Securities Act of 1933, as amended. The Notes and the
common stock issuable upon exchange of the Notes have not been
registered under the Securities Act or any state securities laws
and may not be offered or sold in the United States absent
registration or an applicable exemption from registration
requirements. BioMed Realty Trust has agreed to file a registration
statement regarding resales of the shares of common stock of BioMed
Realty Trust issuable upon exchange of the Notes with the
Securities and Exchange Commission within 180 days of the closing
of this private placement. This release shall not constitute an
offer to sell or the solicitation of an offer to buy any of these
securities, nor shall it constitute an offer, solicitation or sale
in any jurisdiction in which such offer, solicitation or sale is
unlawful. Safe Harbor Statement This press release contains
forward-looking statements based on current expectations, forecasts
and assumptions that involve risks and uncertainties that could
cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: general risks
affecting the real estate industry (including, without limitation,
the inability to enter into or renew leases, dependence on tenants'
financial condition, and competition from other developers, owners
and operators of real estate); adverse economic or real estate
developments in the life science industry or the company's target
markets; risks associated with the availability and terms of
financing, the use of debt to fund acquisitions and developments,
and the ability to refinance indebtedness as it comes due; failure
to manage effectively the company's growth and expansion into new
markets, or to complete or integrate acquisitions and developments
successfully; risks and uncertainties affecting property
development and construction; risks associated with downturns in
the national and local economies, increases in interest rates, and
volatility in the securities markets; potential liability for
uninsured losses and environmental contamination; risks associated
with the company's potential failure to qualify as a REIT under the
Internal Revenue Code of 1986, as amended, and possible adverse
changes in tax and environmental laws; and risks associated with
the company's dependence on key personnel whose continued service
is not guaranteed. For a further list and description of such risks
and uncertainties, see the reports filed by the company with the
Securities and Exchange Commission, including the company's most
recent annual report on Form 10-K and quarterly reports on Form
10-Q. The company disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. DATASOURCE: BioMed
Realty Trust, Inc. CONTACT: Rick Howe, Director, Corporate
Communications of BioMed Realty Trust, Inc., +1-858-207-5859 Web
Site: http://www.biomedrealty.com/
Copyright